What StrataStem does

StrataStem Ltd is a privately held UK contract research organization (CRO) that develops patient-derived induced pluripotent stem cell (iPSC) disease models focused on neurological disorders, with Alzheimer's disease as the lead indication. The company sources tissues from consented neurological disease patients, captures detailed clinical history and disease-associated genotypes (including APOE4), derives iPSCs, and differentiates them into brain cell types to build in vitro models used to study disease mechanisms, identify and validate therapeutic targets, and stratify patients for targeted drug development. Its flagship asset is a portfolio of 200 fully characterized iPSC lines derived from sporadic late-onset Alzheimer's disease patients, with confirmed pluripotency markers and normal karyotype.

The technical platform spans the full iPSC workflow: patient sourcing and tissue processing, iPSC derivation, differentiation to specific brain cell types, 3D neurosphere and blood-brain barrier culture, gene editing (knockout/knock-in, SNPs, INDELs), co-culture systems, 384-well high-content screening for drug toxicity/efficacy/potency, omics analysis for network modelling and differential gene expression, and patient stratification cohort creation. Custom companion assays are developed based on the company's internal know-how and external academic partnerships, including an Honorary Readership affiliation with the University of Manchester held by co-founder Dr. Chris Ward.

Commercially, StrataStem operates a quote-based contract services model, engaging pharmaceutical and biotechnology companies as its primary customer segment and academic research institutions as a secondary segment. The company markets globally via its website and direct business development outreach, with no public pricing, no disclosed funding rounds, and no disclosed revenue. The team visible in source data consists of co-founder/CSO Dr. Chris Ward and Business Development Manager Dr. Stephen France, suggesting a small, founder-led operating profile headquartered at the Alderley Park life science campus in Cheshire, UK.

Name

StrataStem

Legal name

StrataStem Ltd

Website

https://stratastem.com

Company type

Private

Operating status

Operating

Short description

StrataStem Ltd is a UK-based contract research organization that develops patient-derived iPSC disease models and drug screening services for neurological diseases, primarily Alzheimer's, serving pharmaceutical, biotech, and academic clients with a 200-line characterized Alzheimer's iPSC portfolio.

Ownership category

akta.pro rank

Product category

iPSC-based neurological drug discovery services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• IPSC disease models
• Drug discovery services
• Alzheimer's research
• Neurological disease modeling
• Stem cell services

Headquarters

HQ city

Macclesfield

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

StrataStem is a contract research organization that develops and supplies patient-derived induced pluripotent stem cell (iPSC) disease models and runs drug discovery and pharmacology screening services for neurological disease, with a focus on Alzheimer's disease. The company's offering integrates patient sourcing, iPSC derivation, brain cell differentiation, gene editing, 3D neurosphere culture, pharmacology assay development, and omics analysis, anchored by a portfolio of 200 fully characterized iPSC lines from Alzheimer's patients with associated clinical history and genotypic data, enabling client programs in patient stratification and targeted therapeutic development.

Product overview

StrataStem is a biotech company offering a unified platform of iPSC-based disease modeling services and therapeutic discovery solutions. The core offering consists of iPSC Disease Models for identifying disease mechanisms and novel drug targets, Companion Assays for phenotype validation, and Therapeutics Screening services for drug efficacy and toxicity assessment. These are supported by modular service capabilities including patient sourcing and tissue processing, iPSC derivation, brain cell type differentiation, 3D neurosphere and blood-brain barrier culture, gene editing, co-culture systems, omics analysis, and patient stratification. The company's Alzheimer's Disease iPSC Portfolio provides 200 fully characterized cell lines for research applications.

Differentiator

Problem solved

Functional benefit

Products and services

• iPSC Disease Models Patient-derived induced pluripotent stem cell (iPSC) disease models delivered to pharmaceutical, biotechnology, and academic clients for use in disease mechanism studies, target validation, and preclinical drug discovery, with a particular focus on neurological and neurodegenerative diseases.
• Companion Assays Custom-developed pharmacology and disease-relevant assays run on iPSC-derived cellular models, designed to support client preclinical programs in neurological disease research and therapeutic development.
• Therapeutics Screening Therapeutic candidate screening services executed on StrataStem's iPSC-derived neuronal and neurological disease models, enabling clients to evaluate compounds for efficacy, toxicity, and mechanism of action in disease-relevant human cellular systems.
• Alzheimer's Disease iPSC Portfolio A biobank offering of 200 fully characterized induced pluripotent stem cell lines derived from Alzheimer's disease patients, each annotated with clinical history and genotypic data, supplied to clients for use in patient stratification, target validation, and targeted therapeutic development.

Quantifiable outcome

• 200 fully characterized iPSC lines with detailed patient clinical history and APOE genotyping

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• RoslinCT: A UK-based cell therapy and iPSC CDMO providing contract development and manufacturing services. Comparable as a UK-based iPSC services provider, though differentiated by CDMO focus versus StrataStem's discovery CRO model.
• Crown Bioscience: A global CRO providing preclinical and translational drug discovery services including patient-derived models and in vitro screening. Adjacent to StrataStem through patient-derived disease modeling and drug screening services.
• Fujifilm Cellular Dynamics: A major commercial supplier of iPSC-derived cell products and a provider of disease modeling services at scale. Competes with StrataStem through a much broader iPSC product portfolio and established pharma relationships.
• Evotec: A large global drug discovery CRO offering iPSC-based disease modeling, high-content screening, and target validation across multiple therapeutic areas. Overlaps with StrataStem's discovery services but at significantly greater scale and breadth.

Emerging players

• Cellectis: A gene editing company with strong capabilities in iPSC gene editing, including knockout/knock-in and TALEN-based editing. Overlaps with StrataStem's gene editing service module though focused on therapeutic development.
• Reproductive Genetics Institute / iPSC service providers (e.g., CDI, Tempo Bioscience): Emerging iPSC platform companies offering patient-derived disease models and screening services. Comparable scale and indication focus to StrataStem as niche iPSC CROs serving pharma discovery.

Direct peers

• Brainxell: A specialist provider of iPSC-derived neural cell types and neural differentiation services for CNS drug discovery. Directly comparable to StrataStem's brain cell differentiation and neurological disease modeling offering.
• Ncardia: A European iPSC technology company offering iPSC-derived cell products and disease modeling services for drug discovery, including cardiac and neuronal applications. Direct competitor to StrataStem in iPSC-based disease models and contract screening services.
• Axol Bioscience: A specialist iPSC-derived cell supplier focused on neural and cardiovascular cell types for drug discovery and disease modeling. Direct peer in iPSC-based disease models for neurological research applications.
• Newcells Biotech: A UK-based contract research organization specializing in iPSC-derived models, including neural and kidney models, used for drug discovery and toxicity testing. Highly comparable CRO model and indication overlap with StrataStem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stratastem-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StrataStem